Functional variants in the promoter of interleukin-1β are associated with an increased risk of breast cancer:: A case-control analysis in a Chinese population

Interleukin 1 beta (IL-1 beta) is a multifunctional cytokine that upregulates the inflammatory response, and participates in carcinogenesis, malignant transformation, tumor growth, invasion and metastasis. Two potentially functional polymorphisms (T-31C and C-51 IT) in the IL-1 beta gene promoter were suggested to be correlated with alteration of IL-1 beta expression and therefore may be associated with cancer risk. To test the hypothesis that these 2 polymorphisms are associated with risk of breast cancer, we performed a case-control study of 365 breast cancer cases, 270 patients with benign breast diseases (BBD) and 631 cancer-free controls in a Chinese population. Multivariate logistic regression analyses revealed that increased risk of breast cancer was associated with IL-1 beta-31C variant genotypes [adjusted odds ratio (OR) = 1.28 and 95% confidence interval (CI) = 0.91-1.80 for -31CT and 1.72 (95% CI = 1.16-2.54) for -31CC], compared with the -31TT genotype. Similarly, IL-1 beta-511T variant genotypes were also associated with increased risk of breast cancer (adjusted OR = 1.20, 95% CI = 0.86-1.67 for -511CT and adjusted OR = 1.74, 95% CI = 1.182.56 for -511TT), compared with the -511CC genotype. Furthermore, cancer risks associated with IL-1 beta T-31C variant genotypes were more evident in older women, postmenopausal women and individuals with a later menarche age. Interestingly, although we did not find significant associations of these 2 variants with cancer risk when compared with the BBD patients, a 1.27-fold (95% CI = 1.01-1.60) increased risk was observed with the -31C-511T common hap.lotype. These findings indicate that these 2 IL-1 beta promoter variants may contribute to risk of developing breast cancer in the Chinese population. (c) 2005 Wiley-Liss, Inc.